Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May 24:2:13-23.
doi: 10.2147/bctt.s5430.

Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer

Erin M Bertino  1 , Bhuvaneswari Ramaswamy  1
Affiliations
Review

Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer

Erin M Bertino et al. Breast Cancer (Dove Med Press). .

Abstract

Advanced breast cancer represents a therapeutic challenge for oncologists. Chemotherapy with anthracyclines and taxanes has improved survival in this setting, but resistant and refractory disease is common. Ixabepilone, an epothilone, is a recently approved chemotherapeutic agent, both as a single agent and in combination with capecitabine, with efficacy in patients with resistant advanced disease. In this review, the distinctive properties of this drug are discussed, as well as the clinical evidence of efficacy. Ongoing clinical trials are exploring the role of ixabepilone in several clinical settings: neoadjuvant, adjuvant, and novel combinations.

Keywords: chemotherapy; metastatic disease; neoadjuvant chemotherapy; solid tumor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phase I trials of single-agent ixabepilone. Abbreviation: DLT, dose-limiting toxicities; MTD, maximum tolerated dose/recommended phase II dose.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249. - PubMed
    1. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years? J Clin Oncol. 2005;23(8):1760–1775. - PubMed
    1. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–2333. - PubMed
    1. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996;49(6):560–563. - PubMed
    1. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7(5):1429–1437. - PubMed

LinkOut - more resources